Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Cathomas

Showing results (71-80 of 139) with videos related to

Pageof 14
Sort By:
Swiss Medical Weekly|March 11, 2021
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate studySandro Tiziano Stoffel, Roger von Moos, Beat Thürlimann, et al.
British Journal of Cancer|April 17, 2019
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)Alessandra Curioni-Fontecedro, Jean Yannis Perentes, Hans Gelpke, et al.
BMC Cancer|October 8, 2014
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancerMartin Sebastian, Alexandros Papachristofilou, Christian Weiss, et al.
Journal of Bone Oncology|January 24, 2020
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)Michael Mark, Beat Thürlimann, Karin Ribi, et al.
Blood|February 26, 2025
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trialAdalgisa Condoluci, Ilaria Romano, Daniel Dietrich, et al.
BMC Cancer|February 20, 2021
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)Karin Ribi, Beat Thürlimann, Corinne Schär, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2012
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, et al.
British Journal of Cancer|December 16, 2021
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumoursChristian D Fankhauser, Ailsa J Christiansen, Christian Rothermundt, et al.
Clinical Genitourinary Cancer|October 29, 2017
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate CancerDaniel Heinrich, Jasmin Bektic, Andries M Bergman, et al.
The Prostate|July 27, 2016
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)Richard Cathomas, Simon J Crabb, Michael Mark, et al.
Pageof 14

Showing results (71-80 of 139) with videos related to

Sort By:
Pageof 14
Swiss Medical Weekly|March 11, 2021
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate studySandro Tiziano Stoffel, Roger von Moos, Beat Thürlimann, et al.
British Journal of Cancer|April 17, 2019
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)Alessandra Curioni-Fontecedro, Jean Yannis Perentes, Hans Gelpke, et al.
BMC Cancer|October 8, 2014
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancerMartin Sebastian, Alexandros Papachristofilou, Christian Weiss, et al.
Journal of Bone Oncology|January 24, 2020
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)Michael Mark, Beat Thürlimann, Karin Ribi, et al.
Blood|February 26, 2025
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trialAdalgisa Condoluci, Ilaria Romano, Daniel Dietrich, et al.
BMC Cancer|February 20, 2021
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)Karin Ribi, Beat Thürlimann, Corinne Schär, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2012
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, et al.
British Journal of Cancer|December 16, 2021
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumoursChristian D Fankhauser, Ailsa J Christiansen, Christian Rothermundt, et al.
Clinical Genitourinary Cancer|October 29, 2017
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate CancerDaniel Heinrich, Jasmin Bektic, Andries M Bergman, et al.
The Prostate|July 27, 2016
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)Richard Cathomas, Simon J Crabb, Michael Mark, et al.
Pageof 14